Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
montelukast + prednisone
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of montelukast, a leukotriene receptor antagonist, and prednisone, a corticosteroid. Montelukast works by selectively blocking the cysteinyl leukotriene receptor type-1, preventing bronchoconstriction and reducing inflammation in the airways. Prednisone is a corticosteroid that reduces inflammation through multiple pathways. This combination is used primarily for respiratory conditions where both bronchoconstriction and inflammation need to be addressed, such as asthma and mycoplasma pneumonia.
02
Targets
GR (Glucocorticoid receptor)CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)
Beyond the preview
Go deeper on montelukast + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on montelukast + prednisone.